Sustained complete molecular response after imatinib discontinuation in a patient with chronic myeloid leukemia not previously exposed to interferon alpha

Leuk Lymphoma. 2008 Jul;49(7):1399-402. doi: 10.1080/10428190802043903.
No abstract available

Publication types

  • Case Reports
  • Letter
  • Review

MeSH terms

  • Aged
  • Benzamides
  • Cytogenetic Analysis
  • Humans
  • Imatinib Mesylate
  • Interferon-alpha
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
  • Male
  • Piperazines / therapeutic use*
  • Pyrimidines / therapeutic use*
  • Remission Induction / methods

Substances

  • Benzamides
  • Interferon-alpha
  • Piperazines
  • Pyrimidines
  • Imatinib Mesylate